# E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

> **NCT04015336** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 1 (actual)

## Conditions studied

- Papillomavirus Infections
- Oropharyngeal Neoplasms

## Interventions

- **BIOLOGICAL:** E7 T-Cell Receptor (TCR)

## Key facts

- **NCT ID:** NCT04015336
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-06
- **Primary completion:** 2020-07-15
- **Final completion:** 2020-07-15
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Logistical challenges
- **Last updated:** 2022-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04015336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04015336, "E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04015336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*